Literature DB >> 19922706

GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population.

M Chatzimichalis1, J Xenellis, A Tzagaroulakis, P Sarof, K Banis, M Gazouli, A Bibas.   

Abstract

OBJECTIVE: It is well known that laryngeal squamous cell carcinoma is strongly related to tobacco and alcohol consumption. Accumulating evidence suggests that alterations of detoxification enzymes, such as glutathione S-transferases and N-acetyltransferases, influence the risk of cancers associated with tobacco smoke and alcohol.
METHODS: This was a retrospective case-control study. The study group consisted of 88 Greek patients with laryngeal squamous cell carcinoma; there were also 102 control subjects. Frequencies of the genotypes GSTT1, GSTM1, GSTM3 and NAT2 were evaluated by polymerase chain reaction restriction fragment polymorphism.
RESULTS: The distribution of overall genotypes was 55.68 per cent rapid acetylator and 44.32 per cent slow acetylator in patients, and 36.27 per cent rapid acetylator and 63.72 per cent slow acetylator in controls. The odds ratio for rapid acetylator status in cases versus controls was 2.207 (95 per cent confidence interval 1.23-3.95, p = 0.0087).
CONCLUSION: This study demonstrated a significant relationship between rapid acetylator genotypes and laryngeal squamous cell carcinoma in a Greek population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922706     DOI: 10.1017/S002221510999154X

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  13 in total

1.  CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma.

Authors:  Gustavo Jacob Lourenço; Erika Furquim Soledade Neves Silva; José Augusto Rinck-Junior; Carlos Takahiro Chone; Carmen Silvia Passos Lima
Journal:  Tumour Biol       Date:  2011-08-26

2.  GSTM1 null polymorphisms is associated with laryngeal cancer risk: a meta-analysis.

Authors:  Yong Zhang; Wei Chen; Jun-feng Ji; Zhi-yi Wang; Ming-hai Wu; Kai Zhang; Qiu-ping Wang
Journal:  Tumour Biol       Date:  2014-03-19

3.  N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case-control studies.

Authors:  Liang Zhang; Zhaolan Xiang; Rui Hao; Ru Li; Yi Zhu
Journal:  Tumour Biol       Date:  2013-12-13

4.  Quantitative assessment of the association between GSTM1 null genotype and laryngeal cancer risk.

Authors:  Hui Xiao; Minghua Li; Linli Tian; Bin Zha; Ming Liu; Hongchao Yao
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-13       Impact factor: 2.503

5.  Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis.

Authors:  Xin-Jiang Ying; Pin Dong; Bin Shen; Jie Wang; Sang Wang; Guo Wang
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-30       Impact factor: 4.553

6.  Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis.

Authors:  Youyang Zheng; Yong Li; Yaoshu Teng; Zhen Zhang; Xiaolin Cao
Journal:  Oncol Lett       Date:  2011-11-24       Impact factor: 2.967

7.  GSTM1 null genotype is a risk factor for laryngeal cancer.

Authors:  Xuejun Liu; Qijun Fan; Liyan Ni; Fanli Liu; Saiyu Huang; Jinjian Gao; Bobei Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 8.  Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers.

Authors:  Rim Khlifi; Olfa Messaoud; Ahmed Rebai; Amel Hamza-Chaffai
Journal:  Biomed Res Int       Date:  2013-09-16       Impact factor: 3.411

9.  Glutathione S-transferase M1 gene polymorphism and laryngeal cancer risk: a meta-analysis.

Authors:  Xin-Jiang Ying; Pin Dong; Bin Shen; Cheng-Zhi Xu; Hong-Ming Xu; Shu-Wei Zhao
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

10.  Association between GSTM1 and GSTT1 allelic variants and head and neck squamous cell cancinoma.

Authors:  Yang Zhang; Yuanyuan Ni; Hao Zhang; Yongchu Pan; Junqing Ma; Lin Wang
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.